Genfit shares break through their €11.46 resistance on the eve of its results
The Lille-based biotech specialising in liver and metabolic diseases accelerates mid-session in a well-oriented Paris market. The move extends a rebound begun at the end of October and comes on the eve of a quarterly publication.
A €11.46 resistance level broken, above the three moving averages
The stock gains 3.79% to €11.50, while the CAC 40 rises 1.53%. Intraday, it broke upward through its highest level of the last 30 sessions, at €11.46, which has since become a support.
The share price is 22.7% above the MA20 (€9.37), so the one-month rebound of 26.4% does not leave the stock far from its reference levels.
The 18.1% decline over three months is reduced without being erased. The next resistance is at €14.66. Genfit also presented on November 2 at the AASLD congress its strategy in ACLF and its diagnosis of MASH, two areas of its scientific programme.
Third-quarter revenue expected Thursday, November 5
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The company publishes its third-quarter 2026 revenue tomorrow. The previous financial release of this type followed a first half marked by a widening net loss, reaching €86 million for fiscal year 2025 on revenue of €65 million. Over one year, the stock still shows +223.9%, and over the week +8.7%.
At the last session, Genfit had already stood out among the strongest gainers of the SBF 120. It now ranks among the largest gainers of the index, with a rise of 3.79% while the SBF 120 gains 1.49%. The RSI at 61 remains neutral. The November 5 publication will provide the next key figure on the group's activity.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 36,4 millions d'euros
Quarterly revenue: 36,4 millions d'euros
Revenue growth: -7,1 %
Guidance from the release
« conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
